PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 2, 20261 citations

Multi-Omics Analysis Reveals RUNX1-Driven Stemness and Chemoresistance in Pediatric AML

Multi-omics analysis of pediatric minimally differentiated acute myeloid leukemia reveals RUNX1-driven stemness and chemoresistance.

View Full Paper
Ask AI
Bookmark
Share

Authors

TKTatsuya KamitoriSSSatoshi SaidaKMKazuki Mitani

Discussion

Loading...

Member takes

Overview

Randomized trial uncovers RUNX1 alterations linked to poor prognosis in pediatric AML-M0, suggesting new treatment strategies.

Key Points

  • This research aims to uncover the molecular characteristics and treatment challenges of pediatric minimally differentiated acute myeloid leukemia (AML-M0).
  • Conducted a multi-omics analysis of 23 pediatric AML-M0 cases compared to 1483 leukemia samples.
  • Performed functional analyses utilizing CRISPR/Cas9 to knockout RUNX1 in a pediatric AML-M0 cell line.
  • Examined genomic alterations, DNA hypermethylation, and gene expression related to chemotherapy resistance.
  • Identified RUNX1 alterations in 26% of cases, significantly associated with poor prognosis.
  • RUNX1 disruption led to decreased sensitivity to drugs such as cytarabine and anthracyclines.
  • AML-M0 samples exhibited global DNA hypermethylation and transcriptional suppression compared to non-M0 AML.

Cite This Study

Kamitori et al. (2026) studied this question.

synapsesocial.com/papers/69f5943c71405d493afff07ehttps://doi.org/10.1038/s41375-026-02967-6
View Full Paper
Ask AI
Bookmark
Share